Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ChromaDex Corporation - Common Stock (NQ: CDXC )

5.870 +0.290 (+5.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ChromaDex Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
ChromaDex: Q3 Earnings Insights
Via Benzinga
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
From ChromaDex Corporation
Via Business Wire
Earnings Outlook For ChromaDex
Via Benzinga
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide
From ChromaDex Corporation
Via Business Wire
Recap: ChromaDex Q1 Earnings
Via Benzinga
ChromaDex Earnings Perspective: Return On Capital Employed
Via Benzinga
Earnings Preview: ChromaDex
Via Benzinga
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
From ChromaDex Corporation
Via Business Wire
ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line
From ChromaDex Corporation
Via Business Wire
A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients
From ChromaDex Corporation
Via Business Wire
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
From ChromaDex Corporation
Via Business Wire
ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness
From ChromaDex Corporation
Via Business Wire
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
From ChromaDex Corporation
Via Business Wire
Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects
From ChromaDex Corporation
Via Business Wire
ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging
From ChromaDex Corporation
Via Business Wire
ChromaDex to Participate in the LD Micro Invitational XIII
From ChromaDex Corporation
Via Business Wire
ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation Reports First Quarter 2023 Financial Results
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
From ChromaDex Corporation
Via Business Wire
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results
From ChromaDex Corporation
Via Business Wire
ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023
From ChromaDex Corpor
Via Business Wire
Earnings Scheduled For March 8, 2023
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million. 
Via Benzinga
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space
From ChromaDex Corporation
Via Business Wire
A Letter from the ChromaDex Chief Executive Officer
From ChromaDex Corporation
Via Business Wire
ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients
From ChromaDex Corporation
Via Business Wire
ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis
From ChromaDex Corporation
Via Business Wire
ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)
From ChromaDex Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.